What is colorblindness? | Symptoms, causes & treatment

Colorblindness, or color vision deficiency (CVD), is impaired ability to distinguish certain colors due to dysfunction or loss of cone photoreceptors or their photopigments. Congenital CVD most often affects red–green discrimination and is typically X‑linked; acquired CVD arises from retinal or optic nerve disease, medications, or toxins. Symptoms include difficulty telling red from green or blue from yellow, color naming errors, and reliance on brightness rather than hue. Diagnosis uses color vision tests (eg, Ishihara, HRR, Farnsworth D‑15; anomaloscope for classification) and evaluation for ocular/neurologic disease if acquired loss is suspected. Treatment for congenital CVD is supportive (education, accommodations, optional color filters); acquired CVD may improve if the underlying cause is treated.

Key Points

• Most colorblindness is congenital, X‑linked, and red–green; severity is stable over life and visual acuity is otherwise normal.
• Acquired color vision loss is common in macular disease, optic neuropathies, glaucoma, and from medications (eg, ethambutol, digoxin) and often presents as blue–yellow defects, asymmetrically, and may progress.
• Screening plates (Ishihara, HRR) detect CVD; HRR screens both red–green and blue–yellow. Farnsworth D‑15 and anomaloscope testing refine type/severity; ERG supports diagnosis of achromatopsia.
• There is no cure for congenital CVD; management focuses on counseling, safety strategies, and task adaptations. Color‑filter glasses can help in selected situations but do not restore normal color vision (off‑label).
• New or sudden color vision changes, especially in one eye or with pain or vision loss, require urgent evaluation for optic neuritis, retinal disease, or toxic/nutritional optic neuropathy.

Anatomy and Physiology

Color vision depends on three types of cone photoreceptors in the fovea and parafovea:

• L cones (long‑wavelength, “red,” OPN1LW)
• M cones (medium‑wavelength, “green,” OPN1MW)
• S cones (short‑wavelength, “blue,” OPN1SW)

Each expresses an opsin that determines spectral sensitivity. Signals are processed through retinal bipolar and ganglion cells into opponent channels (red–green, blue–yellow) and transmitted via the optic nerve to visual cortex. Disruption at the photopigment, cone, or postreceptoral pathway alters color discrimination.

Etiology

• Congenital (most common)
  • X‑linked variants affecting L/M opsins (protan/deutan; OPN1LW/OPN1MW gene array on Xq28)
  • Autosomal dominant S‑cone defects (tritan; OPN1SW)
  • Monogenic cone dysfunction syndromes (eg, achromatopsia due to CNGA3/CNGB3; blue‑cone monochromacy)
• Acquired
  • Retinal disease: age‑related macular degeneration, diabetic macular edema, central serous chorioretinopathy
  • Optic neuropathies: demyelinating optic neuritis, ischemic optic neuropathy, compressive lesions, glaucoma
  • Toxic/nutritional: ethambutol, linezolid, hydroxychloroquine, digoxin, sildenafil, methanol, solvents; vitamin B12 deficiency
  • Neurologic: occipital lobe injury, Parkinson disease
  • Ocular media: cataract (lenticular yellowing reduces blue transmission)

Pathophysiology

• Congenital anomalous trichromacy results from altered spectral sensitivity of one cone class (eg, protanomaly, deuteranomaly). Dichromacy reflects absence or nonfunction of one cone type (protanopia, deuteranopia, tritanopia). Monochromacy reflects loss of two or all cone pathways; in rod monochromacy (achromatopsia), cones are nonfunctional, causing absent color discrimination, photophobia, nystagmus, and low acuity.
• Acquired CVD typically begins as blue–yellow (tritan) loss with outer retinal disease or media changes; red–green loss is characteristic of optic neuropathy. Asymmetric, progressive, and severity correlates with disease burden.

Epidemiology

• Red–green CVD affects ~8% of males and ~0.5% of females of Northern European ancestry; prevalence varies by ethnicity [1,2].
• Tritan defects are rare congenitally and more often acquired with aging, retinal disease, or media changes [1].
• Achromatopsia is rare (estimated 1:30,000).

Classification

• Congenital
  • Anomalous trichromacy: protanomaly, deuteranomaly, tritanomaly
  • Dichromacy: protanopia, deuteranopia, tritanopia
  • Monochromacy: rod monochromacy (achromatopsia), blue‑cone monochromacy
• Acquired
  • Blue–yellow (tritan) defects (outer retina, media, toxins)
  • Red–green defects (optic neuropathy)
  • Mixed defects in advanced or multi‑site disease

Symptoms and Signs

Congenital red–green deficiency (protan/deutan)

• Lifelong difficulty distinguishing red vs green, brown vs green, and interpreting color‑coded information.
• Reliance on brightness/position (eg, traffic signals); normal fundus exam; normal visual acuity and contrast sensitivity.
• Often detected in school or occupational screening.

Congenital tritan deficiency

• Difficulty distinguishing blue vs green and yellow vs violet; rare.
• Otherwise normal vision; may be unrecognized without testing.

Monochromacy (achromatopsia/blue‑cone monochromacy)

• Marked color blindness (world appears gray), severe photophobia, nystagmus, reduced acuity, hemeralopia (day blindness).
• ERG shows absent or markedly reduced cone responses.

Acquired color vision loss

• New or progressive color desaturation, often blue–yellow; may be asymmetric or unilateral.
• Associated features: decreased acuity (maculopathy), central scotoma (optic neuritis), dyschromatopsia out of proportion to acuity loss (optic neuropathy).
• Medication history positive (eg, ethambutol, digoxin); lens yellowing with age.

Complications

• Safety risks in color‑coded environments (wiring, labeling, maps, lab results, traffic signals).
• Educational impacts in children; misinterpretation as learning difficulties.
• Occupational restrictions in aviation, maritime, rail, electrical trades, and certain public safety roles (standards vary by agency).
• Psychosocial stress; reduced task efficiency.
• For acquired CVD, underlying disease may threaten central vision or indicate neurologic pathology.

Diagnosis

Clinical evaluation

• History: age at onset, symmetry, progression, family history, occupational demands, medication/toxin exposure, systemic disease (diabetes, MS).
• Examination: visual acuity, color testing, pupils (relative afferent pupillary defect), fundus evaluation of macula and optic nerve; consider contrast sensitivity.

Imaging and laboratory testing

• Color vision tests
  • Screening: Ishihara pseudoisochromatic plates (red–green), HRR plates (red–green and blue–yellow).
  • Arrangement: Farnsworth D‑15 (severity/type), Farnsworth‑Munsell 100 Hue (fine discrimination).
  • Anomaloscope (Nagel) for definitive classification/quantification of red–green anomalies; Cambridge Color Test for threshold ellipses.
• Ancillary testing (if acquired suspected)
  • Optical coherence tomography (OCT) of macula and retinal nerve fiber layer.
  • Humphrey visual fields for central/cecocentral scotoma.
  • Full‑field and photopic ERG for cone dysfunction (achromatopsia).
  • Laboratory assessment guided by suspicion (eg, B12, toxin levels).
  • Imaging (MRI) if compressive or demyelinating optic neuropathy is suspected.

Differential diagnosis

Treatment

Medical management

• Congenital CVD
  • Education and environmental adaptations:
  • Use labels/symbols in addition to color; rely on position (eg, standardized traffic lights); adjust device/app settings for high contrast.
  • Digital aids (smartphone apps, color‑naming utilities) for occasional tasks.
  • Optical filters (tinted lenses)
  • Red‑green filters (eg, notch filters) can increase color contrast in specific lighting but do not normalize color perception; effects vary by individual and task; consider supervised trial. Off‑label; not FDA‑approved to treat CVD [3,4].
  • Vision rehabilitation referral for school/occupational accommodations as needed.
• Acquired CVD
  • Treat the underlying disorder (eg, macular edema therapy, corticosteroids for optic neuritis when indicated, glaucoma control).
  • Review and discontinue or adjust offending medications when possible (eg, ethambutol, digoxin) per prescribing clinician; monitor for recovery which may be partial and delayed [5–7].
  • Correct media opacity (eg, cataract surgery) if clinically indicated.
  • Low vision services for persistent deficits.

Representative medication cautions (not treatment for CVD but relevant toxicities):

• Ethambutol: risk of bilateral optic neuropathy with red–green loss; risk increases with dose/duration; color vision testing is useful for monitoring [5].
• Hydroxychloroquine: retinal toxicity screening per AAO guidelines; early changes include paracentral dysfunction; color changes may occur with macular involvement [6].
• Digoxin: xanthopsia (yellow vision) and dyschromatopsia with toxicity [7].

Procedural and surgical management

• No surgical cure exists for congenital red–green CVD.
• Gene therapy research is ongoing for achromatopsia (CNGA3/CNGB3) and other cone dysfunctions; early‑phase human trials are investigational and not standard of care [8,9].
• Cataract extraction may improve acquired blue–yellow loss from lenticular yellowing.

Special populations

• Pediatric: Consider color testing in early school years if concerns arise (errors with crayons, charts). Coordinate with educators for non‑color coding, labeling, and accessibility. Rule out ocular disease if onset is not clearly congenital.
• Pregnancy/lactation: No specific considerations for congenital CVD. For acquired changes, evaluate for preeclampsia/retinal disease if visual symptoms develop.
• Immunocompromised: Higher exposure to medications (eg, linezolid, ethambutol) associated with optic neuropathy; baseline and periodic color testing can aid surveillance.
• Older adults: Expect age‑related blue–yellow shift from lens brunescence; screen for macular disease and glaucoma if new color complaints emerge.

Prognosis

• Congenital red–green CVD is lifelong and nonprogressive; individuals adapt well with strategies and accommodations.
• Acquired CVD prognosis depends on etiology: reversible with medication cessation or cataract surgery; variable recovery after optic neuritis; often persistent in macular degenerations and hereditary cone disorders.

Prevention and Patient Counseling

• Congenital CVD cannot be prevented; offer genetic counseling for families with X‑linked or autosomal dominant traits.
• Reduce risk of acquired CVD by controlling systemic disease (eg, diabetes), avoiding toxins (methanol, solvents), and adhering to monitoring for drugs with known ocular toxicity (eg, ethambutol, hydroxychloroquine).
• Counsel on safety strategies in color‑coded environments; provide documentation of test results for school or workplace accommodations.

When to Seek Immediate Care

• Sudden color vision change, especially in one eye.
• Color desaturation with eye pain or pain on eye movement.
• Color changes with new central blur, dark spot, or reduced vision.
• Color changes soon after starting medications such as ethambutol or digoxin.
• Any color vision change after exposure to methanol or industrial solvents.
• New color vision change with neurologic symptoms (weakness, numbness, speech or balance problems).
  Call 911 for sudden severe vision loss or neurologic symptoms.

References

1. American Academy of Ophthalmology. Color Vision Deficiency. EyeWiki. 2024. https://eyewiki.aao.org/Color_Vision_Deficiency
2. National Eye Institute. Facts About Color Blindness. 2022. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/color-blindness
3. Rabin J, et al. Performance-based measures of red–green color deficiency with filter glasses. Optom Vis Sci. 2020;97(8):573-581. doi:10.1097/OPX.0000000000001554
4. Cochrane Eyes and Vision. Interventions to improve color vision in congenital color vision deficiency. Cochrane Review. 2021.
5. American Academy of Ophthalmology. Ethambutol Toxicity PPP. 2023. https://www.aao.org/education/preferred-practice-pattern
6. Marmor MF, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-1394. doi:10.1016/j.ophtha.2016.01.058
7. StatPearls. Digoxin Toxicity. 2023. https://www.ncbi.nlm.nih.gov/books/NBK431076/
8. Mancuso K, et al. Gene therapy for red–green color blindness in adult primates. Nature. 2009;461(7265):784-787. doi:10.1038/nature08401
9. Fischer MD, et al. Gene therapy for achromatopsia (CNGA3): results of a phase I/II trial. Lancet. 2021;398(10310):1539-1549. doi:

Inline citations correspond to general claims as noted; additional clinical details reflect AAO and NEI summaries [1,2,6].

Disclaimer: This article is for informational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified eye care professional about your specific condition. If you have sudden vision loss, severe eye pain, or an eye injury, seek emergency care immediately.

Author: [AUTHOR NAME], [CREDENTIALS — ASSIGN]
Medical Reviewer: [MEDICAL REVIEWER NAME], [CREDENTIALS — ASSIGN]
Reviewed: July 2026
Last updated: July 2026